Jazz Pharmaceuticals PLC (JAZZ)vsMerck & Company Inc (MRK)
JAZZ
Jazz Pharmaceuticals PLC
$245.80
+2.21%
HEALTHCARE · Cap: $15.58B
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1347% more annual revenue ($66.57B vs $4.60B). JAZZ leads profitability with a 20.4% profit margin vs 4.8%. JAZZ appears more attractively valued with a PEG of 0.96. JAZZ earns a higher WallStSmart Score of 72/100 (B).
JAZZ
Strong Buy72
out of 100
Grade: B
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.8%
Fair Value
$344.71
Current Price
$245.80
$98.91 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 20 of every $100 in revenue as profit
Growing faster than its price suggests
Attractively priced relative to earnings
Strong operational efficiency at 26.9%
15.5% revenue growth
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
3.2% earnings growth
Distress zone — elevated risk
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : JAZZ
The strongest argument for JAZZ centers on Profit Margin, PEG Ratio, P/E Ratio. Profitability is solid with margins at 20.4% and operating margin at 26.9%. Revenue growth of 15.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
JAZZ profiles as a growth stock while MRK is a value play — different risk/reward profiles.
JAZZ carries more volatility with a beta of 0.36 — expect wider price swings.
JAZZ is growing revenue faster at 15.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
JAZZ scores higher overall (72/100 vs 36/100), backed by strong 20.4% margins and 15.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?